Plasma-Lyte 148 with 5% glucose (Solution) Instructions for Use
Marketing Authorization Holder
Baxter Healthcare, Limited (United Kingdom)
Contact Information
Baxter (USA)
ATC Code
B05BB02 (Electrolytes in combination with carbohydrates)
Dosage Form
 |
Plasma-Lyte 148 with 5% glucose | Solution for infusion: containers 500 ml 20 pcs. or 1 L 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for infusion transparent, from colorless to light yellow.
| 1 L | |
| Dextrose | 50 g |
| Sodium chloride | 5.26 g |
| Sodium gluconate | 5.02 g |
| Sodium acetate | 3.68 g |
| Potassium chloride | 370 mg |
| Magnesium chloride | 300 mg |
| Ionic composition: Sodium – 140 mmol/L Potassium – 5 mmol/L Magnesium – 1.5 mmol/L Chloride – 98 mmol/L Acetate – 27 mmol/L Gluconate – 23 mmol/L |
|
500 ml – plastic containers “Viaflex” (1) – plastic bags (20) – cardboard boxes.
1 L – plastic containers “Viaflex” (1) – plastic bags (10) – cardboard boxes.
500 ml – plastic containers “Viaflo” (1) – plastic bags (20) – cardboard boxes.
1 L – plastic containers “Viaflo” (1) – plastic bags (10) – cardboard boxes.
Clinical-Pharmacological Group
Drug for rehydration and detoxification for parenteral use
Pharmacotherapeutic Group
Electrolyte balance restoring agent
Pharmacological Action
Plasma-Lyte 148 with 5% glucose corrects the acid-base state, replenishes fluid and electrolyte deficiency, enhances diuresis, has an antiplatelet property, reduces metabolic acidosis, improves microcirculation, and has detoxifying and anti-shock effects.
Glucose enhances redox processes in the body and covers part of the body’s energy expenditure, as it is a source of easily digestible carbohydrates. During the metabolism of glucose in tissues, a significant amount of energy necessary for the body’s vital functions is released.
Indications
Plasma-Lyte 148 with 5% glucose is used in adults and children as a component of infusion therapy:
- In the complex treatment of shock;
- In thermal injury;
- In acute blood loss;
- In hypotonic and isotonic forms of hypohydration;
- In metabolic acidosis in severely ill patients;
- For correction of water-salt balance;
- In acute diffuse peritonitis and intestinal obstruction;
- For the treatment of patients with intestinal fistulas;
- In decompensation of electrolyte disorders;
- In patients with acute intestinal infections;
- In dehydration and metabolic acidosis;
The volemic effect of the drug is short-lived; in the treatment of severe hypovolemia, combination with colloidal solutions, as well as blood and its components, is recommended.
ICD codes
| ICD-10 code | Indication |
| A09 | Other and unspecified gastroenteritis and colitis of infectious origin |
| E86 | Volume depletion (including dehydration, hypovolemia) |
| E87 | Other disorders of fluid, electrolyte and acid-base balance |
| E87.2 | Acidosis |
| K65 | Peritonitis |
| R57 | Shock, not elsewhere classified |
| R58 | Hemorrhage, not elsewhere classified |
| T30 | Burns and corrosions of unspecified body region |
| ICD-11 code | Indication |
| 1A40.Z | Infectious gastroenteritis or colitis, unspecified |
| 5C70.Z | Decrease of volume of fluid [hypovolemia], unspecified |
| 5C73.Z | Acidosis, unspecified |
| 5C7Z | Other disorders of fluid, electrolyte and acid-base balance |
| DC50.Z | Peritonitis, unspecified |
| MG27 | Hemorrhage, not elsewhere classified |
| MG40.Z | Shock, unspecified |
| NE11 | Burn of unspecified body region |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
The drug is used under the control of laboratory tests.
It is administered intravenously (bolus and drip). Before administration, the solution is warmed to body temperature.
The daily dose for adults is 5-20 ml/kg, if necessary it can be increased to 30-40 ml/kg. It is administered at a rate of 60-80 drops/min, bolus administration is allowed. The daily dose for children is 5-10 ml/kg, the administration rate is 30-60 drops/min. The course of treatment is 3-5 days.
Adverse Reactions
Possible development of hyperkalemia.
Possible vein irritation and thrombophlebitis at the injection site.
Contraindications
- Alkalosis;
- Hypertonic dehydration;
Administration of large volumes of fluid is contraindicated.
Use in Hepatic Impairment
In patients with hepatic insufficiency, it is necessary to monitor the level of electrolytes in plasma.
Use in Renal Impairment
In patients with renal insufficiency, it is necessary to monitor the level of electrolytes in plasma.
Pediatric Use
The daily dose for children is 5-10 ml/kg, the administration rate is 30-60 drops/min. The course of treatment is 3-5 days.
Special Precautions
In patients with renal, cardiac, or hepatic insufficiency, it is necessary to monitor the level of electrolytes in plasma.
It is recommended to replace all devices for intravenous infusion at least once a day.
Careful and aseptic mixing of additional substances is mandatory. After mixing, the solution, if not administered immediately, should be stored at a temperature from 2°C (35.6°F) to 8°C (46.4°F) for 24 hours.
Do not administer a cloudy solution or from a damaged container.
Storage Conditions
Store in a place inaccessible to children at a temperature up to 25°C (77°F). Do not freeze.
Shelf Life
The shelf life is 2 years. The drug should be used before the date indicated on the packaging.
Dispensing Status
The drug is dispensed by prescription. For healthcare institutions.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer![Plasma-Lyte 148 with 5% glucose [Solution] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Plasma-Lyte 148 with 5% glucose [Solution] 2")